T-cell mediated suppression of neuroblastoma following fractalkine gene therapy is amplified by targeted IL-2Yan Zeng, aus Chongqing, V.R.ChinaPreface11123605#11245252.12.262.32.3.12.3.272.42.58439#452.62.739605#1783.13.210377#20911604#2423.3423#24812587#3643.413605#324605#2263.514564#6003.615604#3283.716600#247432#3074171819AbkürzungsverzeichnisLiteraturverzeichnisAnteilserklärungAcknowledgmentEidestattliche ErklärungdeInhaltsverzeichnisHilfe Literaturverzeichnis 5.1 Own Publications [1] Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN.: Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol. 2005 Jul;42(11) , 1311-9. [2]. Huebener,N.; Lange,B.; Lemmel,C.; Rammensee,H.G.; Strandsby,A.; Wenkel,J.; Jikai,J.; Zeng,Y.; Gaedicke,G.; Lode,H.N.: Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett. 2003 ; Jul 18;197(1-2) , 211-7. [3]. Lode,H.N.; Huebener,N.; Zeng,Y.; Fest,S.; Weixler,S.; Gaedicke,G.: DNA minigene vaccination for adjuvant neuroblastoma therapy. Ann N Y Acad Sci. 2004 Dec;1028, 113-21. [4]. Zeng Y; Jiang J ; Huebener N ; Wenkel J ; Gaedicke G ; Xi a ng R ; Lode HN. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett. 2005 Jun 10. 5.2 Publications of other authors (1) Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA.: Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol. 2000 , 35(6), 641-646. (2) Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA et al.: Neurotactin a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997 ; 387(6633), 611-617. (3) Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D et al.: A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 ; 385(6617), 640-644. (4) Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T.: Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004 , 24(1), 34-40. (5) Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ et al.: Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem. 2001 ; 276(41), 37993-38001. (6) Moser B, Loetscher P.: Lymphocyte traffic control by chemokines, Nat Immunol. 2001 , 2(2), 123-128. (7) Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T et al.: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998 , 188(8), 1413-1419. (8) Haskell CA, Cleary MD, Charo IF.: Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem. 1999 , 274(15), 10053-10058. (9) Moatti D, Faure S, Fumeron F, Amara M, Seknadji P, McDermott DH et al.: Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001 , 97(7), 1925-1928. (10) Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M et al.: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997 , 91(4), 521-530. (11) Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M et al.: Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168(1) , 6173-6180. (12) Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A et al.: Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107(9), 1173-1181. (13) Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, Okazaki T et al.: Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 2003, 33(1), 53-58. (14) Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K et al.: Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002, 46(11), 2878-2883. (15) Borrello I, Pardoll D.: GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002, 13(2), 185-193. (16) Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD.: Reisfeld RA. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A 1999, 96(15) , 8591-8596. (17) Becker JC, Pancook JD, Gillies SD, Furukawa K.: Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996, 183(5), 2361-2366. (18) Xiang R, Lode HN, Gillies SD., Reisfeld RA.: T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 1999, 163(7), 3676-3683. (19) Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004 ; 16(6), 542-546. (20) Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy . Blood 1998 ; 91(5), 1706-1715. (21) Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993 ; 14(6), 281-284. (22) Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol Immunol 1991 ; 28(3), 279-284. (23) Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990 ; 344(6269),873-875. (24) Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998 ; 4(3), 321-327. (25) Xin H, Kikuchi T, Andarini S, Ohkouchi S, Suzuki T, Nukiwa T et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005 ; 35(5),1 371-1380. (26) Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997 ; 89(21),1586-1594. (27) Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996 ; 183(5) , 2361-2366. (28) Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997 ; 57(21), 4948-4955. (29) Xiang R, Lode HN, Gillies SD, Reisfeld RA. T cell memory against colon carcinoma is long-lived in the absence of antigen . J Immunol 1999; 163(7 , 3676-3683. (30) Niethammer D, Handgretinger R.: Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 1995, 31A(4):568-571. (31) Roth JA, Cristiano RJ.: Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997. 89(1), 21-39. (32) Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA.: An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A 1996, 93(15), 7826-7831. (33) Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA.: Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996. 98(12), 2801-2804. (34) Xiang R, Lode HN, Dreier T, Gillies SD, Reisfeld RA.: Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res 1998. 58(17), 3918-3925.